Glaukos NASDAQ:GKOS disclosed an insider stock sale by Senior Vice President and Chief Financial Officer Alex R. Thurman, who sold 625 shares of the company's common stock on March 17 at $99.15 per share. The sale produced gross proceeds of $61,968 and, according to a Form 4 filed with the Securities and Exchange Commission, was carried out under a Rule 10b5-1 trading plan that the insider adopted on December 15, 2025.
Separately, the filing shows that on March 16 Glaukos withheld 614 shares to satisfy tax obligations triggered by the vesting of restricted stock units. That withholding was recorded at a per-share price of $98.94, yielding a total value of $60,749 for the shares used to cover taxes.
After those transactions, Thurman is reported to directly hold 49,249 shares of Glaukos stock. That total includes 12,512 unvested restricted stock units and 167 shares acquired through the company’s Employee Stock Purchase Plan. The Form 4 provides the procedural and numerical details of the sale and the tax-related withholding, indicating both a planned sale under an established trading plan and the routine settlement treatment for vested equity awards.
These insider moves come as Glaukos shares are trading at $102.09 and the company carries a market valuation of $5.92 billion. InvestingPro analysis cited in the filing commentary characterizes the stock as appearing overvalued at current market levels. The analysis notes that while Glaukos has delivered robust top-line momentum - with revenue growing 32% over the last twelve months - the company remains unprofitable and has seen earnings estimates trimmed by analysts, with 10 analysts recently revising earnings downward.
Alongside the disclosure of Thurman’s transactions, the company has announced a series of operational and regulatory developments. Glaukos received FDA approval for an NDA labeling supplement that permits re-administration of its iDose TR product, a change aimed at expanding treatment options for glaucoma patients. The approval has been followed by broker adjustments: BTIG raised its price target to $131 from $123 and maintained a Buy rating, while Stifel reiterated a Buy rating and kept a $160 price target, pointing to positive momentum for the company’s iDose and Epioxa products despite potential LCD restrictions. Needham also increased its target to $127 from $125 and maintained a Buy rating, noting that Glaukos’ fourth-quarter 2025 revenue matched its preannouncement.
Company management has maintained its 2026 revenue guidance, forecasting that iDose readministration will contribute to volume growth in the latter half of 2026. Stifel’s survey of respondents, as reported, suggests that even with potential combination utilization restrictions, the risk-reward profile for iDose is viewed favorably by some market participants. Collectively, these analyst actions and regulatory milestones are presented as indicators of ongoing investor interest in Glaukos’ product-led growth prospects.
Investors seeking additional context are pointed to InvestingPro’s expanded research coverage, which includes a Pro Research Report for GKOS and coverage of more than 1,400 other U.S. stocks. The filing and accompanying market commentary provide a snapshot of insider activity, company fundamentals, regulatory progress, and analyst sentiment at a moment when Glaukos navigates both operational advances and valuation scrutiny.